drugset
drugset / Trial / NCT03375502

A Study of MG1111 in Healthy Children

NCT03375502 ↗

Phase 2/3 Completed 814 enrolled Green Cross Corporation
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus comparator

Timeline

Start
2016-11-26
Primary completion
2019-01-29
Completion
2019-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MG1111 Vaccine 0.5 ml Subcutaneous

Indications

No indication recorded.